Metabolic (cytoprotective) therapy of menopausal disturbances

The paper presents modern views on cardiovascular aspects of menopause and metabolic therapy of menopausal disturbances with meldonium (Mildronate®). The role of estrogen deficiency in climacteric disturbance development, key pathogenetic mechanisms of menopausal metabolic syndrome (MS), and relevan...

Full description

Saved in:
Bibliographic Details
Published inKardiovaskuli͡a︡rnai͡a︡ terapii͡a︡ i profilaktika Vol. 10; no. 3; pp. 72 - 75
Main Authors Tolstov, S. N., Mychka, V. B.
Format Journal Article
LanguageEnglish
Russian
Published SILICEA-POLIGRAF» LLC 20.06.2011
Subjects
arterial hypertension
menopausal metabolic syndrome
menopause
metabolic therapy
mildronate
Online AccessGet full text

Cover

More Information
Summary:The paper presents modern views on cardiovascular aspects of menopause and metabolic therapy of menopausal disturbances with meldonium (Mildronate®). The role of estrogen deficiency in climacteric disturbance development, key pathogenetic mechanisms of menopausal metabolic syndrome (MS), and relevant features of arterial hypertension and endothelial dysfunction development are discussed. The data on Mildronate® clinical use for cardiovascular prevention are summarized. The wide prevalence and multiple clinical manifestations of menopausal disturbances point to the need for their complex therapy. Mildronate® therapy is a new approach for systemic correction of metabolic disturbances in women with climacteric symptoms and menopausal MS.
ISSN:1728-8800
2619-0125
DOI:10.15829/1728-8800-2011-3-72-75